An overview of rational design of mRNA-based therapeutics and vaccines

References

• Wang F, Zuroske T, Watts JK. RNA therapeutics on the rise. Nat Rev Drug Discov. 2020;19(7):441–442.
   PubMed Web of Science ®Google Scholar
• Wolff JA, Malone RW, Williams P, et al., Direct gene transfer into mouse muscle in vivo. Science. 247(4949): 1465–1468. 1990.
   PubMed Web of Science ®Google Scholar
• Burnett JC, Rossi JJ. RNA-based therapeutics: current progress and future prospects. Chem Biol. 2012;19(1):60–71.
   PubMed Web of Science ®Google Scholar
• Geall AJ, Mandl CW, Ulmer JB. RNA: the new revolution in nucleic acid vaccines. Semin Immunol. 2013;25(2):152–159.
   PubMed Web of Science ®Google Scholar
• Hajj KA, Whitehead KA. Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat Rev Mater. 2017;2(10):17056.
   Web of Science ®Google Scholar
• Kallen KJ, Thess A. A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleoside-based vaccines and drugs. Ther Adv Vaccines. 2014;2(1):10–31.
   PubMedGoogle Scholar
• Kreiter S, Diken M, Selmi A, et al. Tumor vaccination using messenger RNA: prospects of a future therapy. Curr Opin Immunol. 2011;23(3):399–406.
   PubMed Web of Science ®Google Scholar
• Sahin U, Kariko K, Turecu O. mRNA-based therapeutics-developing a new class of drugs. Nat Rev Drug Discov. 2014;13:759–780.
   PubMed Web of Science ®Google Scholar
• Kariko K, Muramatsu H, Ludwig J, et al. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 2011;38(21):e142.
   Google Scholar
• Youn H, Chung JK. Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy. Expert Opin Biol Ther. 2015;15(9):1337–1348.
   PubMed Web of Science ®Google Scholar
• Steichen C, Luce E, Maluenda J, et al. Messenger RNA versus retrovirus-based induced pluripotent stem cell reprogramming strategies: analysis of genomic integrity. Stem Cells Tansl Med. 2014;3(6):686–691.
   PubMed Web of Science ®Google Scholar
• Nair SK, Boczkowski D, Morse M, et al., Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol. 16(4): 364–369. 1998.
   PubMed Web of Science ®Google Scholar
• Heiser A, Coleman D, Dannull J, et al., Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest. 109(3): 409–417. 2002.
   PubMed Web of Science ®Google Scholar
• Weide B, Carralot JP, Reese A, et al. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother. 2008;31(2):180–188.
   PubMed Web of Science ®Google Scholar
• Rittig SM, Haemtschel M, Weimer KJ, et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther. 2011;19(5):990–999.
   PubMed Web of Science ®Google Scholar
• Van Gulck E, Vlieghe E, Vekemans M, et al. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. AIDS. 2012;26(4):F1–12.
   PubMed Web of Science ®Google Scholar
• Maus MV, Haas AR, Beatty GL, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol Res. 2013;1(1):26–31.
   PubMed Web of Science ®Google Scholar
• Wilgenhof S, Corthals J, Heirman C, et al. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. J Clin Oncol. 2016;34(12):1330–1338.
   PubMed Web of Science ®Google Scholar
• Bahl K, Senn JJ, Yuzhakov O, et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol Ther. 2017;25(6):1316–1327.
   PubMed Web of Science ®Google Scholar
• Leal L, Guardo AC, Moron-Lopez S, et al. Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection. AIDS. 2018;32(17):2533–2545.
   PubMed Web of Science ®Google Scholar
• de Jong W, Leal L, Buyze J, et al. Therapeutic vaccine in chronically HIV-1-infected patients: a randomized, double-blind, placebo-controlled phase IIa trial with HTI-TriMix. Vaccines (Basel). 2019;7(4):209.
   Web of Science ®Google Scholar
• Papachristofilou A, Hipp MM, Klinkhardt U, et al. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J Immunother Cancer. 2019;7(1):38.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 – preliminary report. N Engl J Med. 2020;383(20):1920–1931.
   PubMed Web of Science ®Google Scholar
• Trepotec Z, Lichteneggeer E, Plank C, et al. Delivery of mRNA therapeutics for the treatment of hepatic diseases. Mol Ther. 2019;27(4):794–802.
   PubMed Web of Science ®Google Scholar
• Magadum A, Kaur K, Zangi L. mRNA-based protein replacement therapy for the heart. Mol Ther. 2019;27(4):785–793.
   PubMed Web of Science ®Google Scholar
• Warren L, Lin C. mRNA-based genetic reprogramming. Mol Ther. 2019;27(4):729–734.
   PubMed Web of Science ®Google Scholar
• Schlake T, Thran M, Fiedler K, et al. mRNA: a novel avenue to antibody therapy? Mol Ther. 2019;27(4):773–784.
   PubMed Web of Science ®Google Scholar
• Restifo NP, Ying H, Hwang L, et al. The promise of nucleic acid vaccines. Gene Ther. 2000;7(2):89–92.
   PubMed Web of Science ®Google Scholar
• Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet. 2008;9(10):776–788.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Porter FW, et al., mRNA vaccines – a new era in vaccinology. Nat Rev Drug Discov. 17(4): 261–279. 2018.
   PubMed Web of Science ®Google Scholar
• Alexopoulou L, Holt AC, Medzhitov R, et al. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413(6857):732–738.
   PubMed Web of Science ®Google Scholar
• Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006;441(7089):101–105.
   PubMed Web of Science ®Google Scholar
• Nallagatla SR, Hwang J, Toroney R, et al. 5ʹ-triphosphate-dependent activation of PKR by RNAs with short stem-loops. Science. 2007;318(5855):1455–1458.
   PubMed Web of Science ®Google Scholar
• Anderson BR, Muramatsu H, Nallagatla SR, et al. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res. 2010;38(17):5884–5892.
   PubMed Web of Science ®Google Scholar
• Kariko K, Buckstein M, Ni H, et al. Suppression of RNA recognition of toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005;23(2):165–175.
   PubMed Web of Science ®Google Scholar
• Kariko K, Muramatsu H, Welsh FA, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16:183301840.
   Web of Science ®Google Scholar
• Warren L, Manos PD, Ahfeldt T, et al. Highly efficient reprogramming to pluropotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell. 2010;7(5):618–630.
   PubMed Web of Science ®Google Scholar
• Song J, Yi C. Chemical modifications to RNA: a new layer of gene expression regulation. ACS Chem Biol. 2017;12(2):316–325.
   PubMed Web of Science ®Google Scholar
• Mauer J, Luo X, Blanjoie A, et al. Reversible methylation of m(6)Am in the 5ʹ cap controls mRNA stability. Nature. 2017;541(7637):371–375.
   PubMed Web of Science ®Google Scholar
• Wadhwa A, Aljabbari A, Lokras A, et al. Opportunities and challenges in the delivery of mRNA-based vaccines. Pharmaceutics. 2020;12(2):102.
   PubMed Web of Science ®Google Scholar
• Ramanathan A, Robb GB, Chan SH. mRNA capping: biological functions and applications. Nucleic Acids Res. 2016;44(16):7511–7526.
   PubMed Web of Science ®Google Scholar
• Jemielity J, Fowler T, Zuberek J, et al. Novel “anti-reverse” cap analogs with superior translational properties. RNA. 2003;9(9):1108–1122.
   PubMed Web of Science ®Google Scholar
• Kuhn AN, Diken M, Kreiter S, et al. Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immate dendritic cells and induce superior immune responses in vivo. Gene Ther. 2010;17(8):961–971.
   PubMed Web of Science ®Google Scholar
• Stepinski J, Waddell C, Stolarski R, et al. Synthesis and properties of mRNAs containing the novel “anti-reverse” cap analogs 7-methyl(3ʹ-O-methyl)GpppG and 7-methyl(3ʹ-deoxy)GpppG. RNA. 2001;7(10):1486–1495.
   PubMed Web of Science ®Google Scholar
• Muttach F, Muthmann N, Rentmeister A. Synthetic mRNA capping. Beilstein J Org Chem. 2017;13:2819–2832.
   PubMed Web of Science ®Google Scholar
• Zohra FT, Chowdhury EH, Tada S, et al. Effective delivery with enhanced translational activity synergistically accelerates mRNA-based transfection. Biochem Biophys Res Comm. 2007;358(1):373–378.
   PubMed Web of Science ®Google Scholar
• Kocmik I, Piecyk K, Rudzinska M, et al. Modified ARCA analogs providing enhanced translational properties of capped mRNAs. Cell Cycle. 2018;17(13):1624–1636.
   PubMed Web of Science ®Google Scholar
• Strenkowska M, Kowalska J, Lukaszewicz M, et al. Towards mRNA with superior translational activity: synthesis and properties of ARCA tetraphosphates with single phosphorothioate modifications. New J Chem. 2010;34(5):993–1007.
   PubMed Web of Science ®Google Scholar
• Sikorksi PJ, Warminski M, Kubacka D, et al. The identity and methylation status of the first transcribed nucleotide in eukaryotic mRNA 5ʹ cap modulates protein expression in living cells. Nucleic Acids Res. 2020;48(3):1604–1626.
   PubMedGoogle Scholar
• Dimitrova DG, Teysset L, Carre C. RNA 2ʹ-O-methylation (Nm) modification in human diseases. Genes (Basel). 2019;10(2):117.
   Web of Science ®Google Scholar
• Picard-Jean F, Brand C, Tremblay-Letourneau M, et al. 2ʹ-O-methylation of the mRNA cap protects RNAs from decapping and degradation by DXO. PLoS One. 2018;13(3):e0193804.
   PubMed Web of Science ®Google Scholar
• Devarkar SC, Wang C, Miller MT, et al. Structural basis for m7G recognition and 2ʹ-O-methyl discrimination in capped RNAs by the innate immune receptor RIG-I. Proc Natl Acad Sci USA. 2016;113(3):596–601.
   PubMed Web of Science ®Google Scholar
• Vaidyanathan S, Azizian KT, Haque A, et al. Uridine depletion and chemical modification increase Cas9 mRNA activity and reduce immunogenicity without HPLC purification. Mol Ther Nucleic Acids. 2018;12:530–542.
   PubMedGoogle Scholar
• McCaffrey AP. RNA epitranscriptome: role of the 5ʹ Cap. Genet Eng Biotechnol News. 2019;39:59–61.
   Google Scholar
• Thess A, Grund S, Mui BL, et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol Ther. 2015;23(9):1456–1464.
   PubMed Web of Science ®Google Scholar
• Sharp PM, Li WH. The codon adaptation index – a measure of directional synonymous codon usage bias, and its potential applications. Nucleic Acids Res. 1987;15(3):1281–1295.
   PubMed Web of Science ®Google Scholar
• Qian W, Yang JR, Pearson NM, et al. Balanced codon usage optimizes eukaryotic translational efficiency. PLoS Genet. 2012;8(3):e1002603.
   PubMed Web of Science ®Google Scholar
• Saunders R, Deane CM. Synonymous codon usage influences the local protein structure observed. Nucleic Acids Res. 2010;38(19):6719–6728.
   PubMed Web of Science ®Google Scholar
• Plotkin JB, Kudla G. Synonymouc but not the same: the causes and consequences of codoon bias. Nat Rev Genet. 2011;12(1):32–42.
   PubMed Web of Science ®Google Scholar
• Fath S, Bauer AP, Liss M, et al., Multiparameter RNA and codon optimization: a standardized tool to assess and enhance autologous mammalian gene expression. PLoS One. 6(3): e17596. 2011.
   PubMed Web of Science ®Google Scholar
• Gustafsson C, Govindarajan S, Minshull J. Codon bias and heterologous protein expression. Trends Biotechnol. 2004;22(7):346–353.
   PubMed Web of Science ®Google Scholar
• Linares-Fernandez S, Lacroix C, Exposito JY, et al. Tailoring mRNA vaccine to balance innate/adapative immune response. Trends Mol Med. 2020;26(3):311–323.
   PubMed Web of Science ®Google Scholar
• Angov E, Hillier CJ, Kincaid RL, et al. Heterologous protein expression is enhanced by harmonizing the codon usage frequencies of the target gene with those of the expression host. PLoS One. 2008;3(5):e2189.
   PubMed Web of Science ®Google Scholar
• Bali V, Bebok Z. Decoding mechanisms by which silent codon changes influence protein biogenesis and function. Int J Biochem Cell Biol. 2015;64:58–74.
   PubMed Web of Science ®Google Scholar
• Hinnebusch AG, Ivanov IP, Sonenberg N. Translational control by 5ʹ-untranslated regions of eukaryotic mRNAs. Science. 2016;352(6292):1413–1416.
   PubMed Web of Science ®Google Scholar
• Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell. 2009;136(4):731–745.
   PubMed Web of Science ®Google Scholar
• Haizel SA, Bhardwaj U, Gonzalez RL Jr, et al. 5ʹUTR recruitment of the translation initiation factor eIF4GI or DAP5 drives cap-independent translation of a subset of human mRNAs. J Biol Chem. 2020;295(33):11693–11706.
   PubMed Web of Science ®Google Scholar
• Svitkin YV, Pause A, Haghighat A, et al. The requirement for eukaryotic initiation factor 4A (elF4A) in translation is in direct proportion to the degree of mRNA5ʹ secondary structure. RNA. 2001;7(3):382–394.
   PubMed Web of Science ®Google Scholar
• Barreau C, Paillard L, Osborne HB. AU-rich elements and associated factors: are there unifying principles? Nucleic Acids Res. 2005;33(22):22.
   Web of Science ®Google Scholar
• Eberhardt W, Doller A, Akoolel S, et al. Modulation of mRNA stability as a novel therapeutic approach. Pharmacol Ther. 2007;114(1):56–73.
   PubMed Web of Science ®Google Scholar
• Wilkinson N, Pantopoulos K. The IRP/IPE system in vivo: insights from mouse models. Front Pharmacol. 2014;5:176.
   PubMed Web of Science ®Google Scholar
• Asrani KH, Farelli JD, Stahley MR, et al., Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA. RNA Biol. 15(6): 756–762. 2018.
   PubMed Web of Science ®Google Scholar
• Yu S, Kim VN. A tale of non-canonical tails: gene regulation by post-transcriptional RNA tailing. Nat Rev Mol Cell Biol. 2020;21(9):542–556.
   PubMed Web of Science ®Google Scholar
• Tang TT, Passmore LA. Recognition of poly(A) RNA through its intrinsic helical structure. Cold Spring Harb Symp Quant Biol. 2019;84:21–30.
   PubMedGoogle Scholar
• Elango N, Elango S, Shivshankar P, et al. Optimized transfection of mRNA transcribed from a d(A/T)100 tail-containing vector. Biochem Biophys Res Comm. 2005;330(3):958–966.
   PubMed Web of Science ®Google Scholar
• Peng J, Murray EL, Schoenberg DR. In vivo and in vitro analysis of poly(A) length effects on mRNA translation. Methods Mol Biol. 2008;419:215–230.
   PubMedGoogle Scholar
• Oh S, Kessler JA. Design, assembly, production, and transfection of synthetic modified mRNA. Methods. 2018;133:29–43.
   PubMed Web of Science ®Google Scholar
• Sachs AB, Varani G. Eukaryotic translation initiation: there are (at least) two sides to every story. Nat Struct Biol. 2000;7(5):356–361.
   PubMedGoogle Scholar
• Holtkamp S, Kreiter S, Selmi A, et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood. 2006;108(13):4009–4017.
   PubMed Web of Science ®Google Scholar
• Weissman D. mRNA transcript therapy. Expert Rev Vaccines. 2015;14(2):265–281.
   PubMed Web of Science ®Google Scholar
• Voet D, Voet JG. Biochemistry. 4th ed. New York: John Wiley & Sons; 2011.
   Google Scholar
• Kariko K, Ni H, Capodici J, et al. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem. 2004;279(13):12542–12550.
   PubMed Web of Science ®Google Scholar
• Yamamoto A, Kormann M, Rosenecker J, et al., Current prospects for mRNA gene delivery. Eur J Pharm Biopharm. 71(3): 484–489. 2009.
   PubMed Web of Science ®Google Scholar
• Tews BA, Meyers G. Self-replicating RNA. Methods Mol Biol. 2017;1499:15–35.
   PubMedGoogle Scholar
• Ying H, Zaks TZ, Wang RF, et al. Cancer therapy using a self-replicating RNA vaccine. Nat Med. 1999;5(7):823–827.
   PubMed Web of Science ®Google Scholar
• Bloom K, van den Berg F, Arbuthnot P. Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 2020 Oct;22:1–13.
   Google Scholar
• Lundstrom K. Self-replicating RNA viruses for RNA therapeutics. Molecules. 2018;23(12):3310.
   PubMed Web of Science ®Google Scholar
• Maruggi G, Zhang C, Li J, et al. mRNA as a transformative technology for vaccine development to control infectious diseases. Mol Ther. 2019;27(4):757–772.
   PubMed Web of Science ®Google Scholar
• Hyde JL, Chen R, Trobaugh DW, et al. The 5ʹ and 3ʹ ends of alphavirus RNAs – non-coding is not non-functional. Virus Res. 2015;206:99–107.
   PubMed Web of Science ®Google Scholar
• Toribio R, Diaz-Lopez I, Boskovic J, et al. An RNA trapping mechanism in Alphavirus mRNA promotes ribosome stalling and translation initiation. Nucleic Acids Res. 2016;44(9):4368–4380.
   PubMed Web of Science ®Google Scholar
• Hyde JL, Gardner CL, Kimura T, et al. A viral RNA structural element alters host recognition of nonself RNA. Science. 2014;343(6172):783–787.
   PubMed Web of Science ®Google Scholar
• Reynaud JM, Kim DY, Atasheva S, et al. IFIT1 differentially interferes with translation and replication of alphavirus genomes and promotes induction of type I interferon. PLoS Pathog. 2015;11(4):e1004863.
   PubMed Web of Science ®Google Scholar
• Trobaugh DW, Gardner CL, Sun C, et al. RNA viruses can hijack vertebrate microRNAs to suppress innate immunity. Nature. 2014;506(7487):245–248.
   PubMed Web of Science ®Google Scholar
• Li Y, Teague B, Zhang Y, et al. In vitro evolution of enhanced RNA replicons for immunotherapy. Sci Rep. 2019;9(1):6932.
   PubMedGoogle Scholar
• Mc Cafferty S, De Temmerman J, Kitada T, et al. In vivo validation of a reversible small molecule-based switch for synthetic self-amplifying mRNA regulation. Mol Ther. 2020 Nov 11;20(S1525–0016):30608.
   Google Scholar
• Utt A, Quirin T, Saul S, et al. Versatile trans-replication systems for Chikungunya Virus allow functional analysis and tagging of every replicase protein. PLoS One. 2016;11(3):e0151616.
   PubMed Web of Science ®Google Scholar
• Blakney AK, McKay PF, Shattock RJ. Structural components for amplification of positive and negative strand VEEV splitzicons. Front Mol Biosci. 2018;5:71.
   PubMed Web of Science ®Google Scholar
• Bartholomeeusen K, Utt A, Coppens S, et al. A Chikungunya virus trans-replicase system reveals the importance of delayed nonstructural polyprotein processing for efficient replication complex formation in mosquito cells. J Virol. 2018;92(14):e00152–18.
   PubMed Web of Science ®Google Scholar
• Smerdou C, Liljestrom P. Two-helper RNA system for production of recombinant Semliki forest virus particles. J Virol. 1999;73(2):1092–1098.
   PubMed Web of Science ®Google Scholar
• Beissert T, Perkovic M, Vogel A, et al., A trans-amplifying RNA vaccine strategy for induction of potent protective immunity. Mol Ther. 28(1): 119–128. 2020.
   PubMed Web of Science ®Google Scholar
• Read ML, Singh S, Ahmed Z, et al. A versatile reducible polycation-based system for efficient delivery of a broad range of nucleic acids. Nucleic Acids Res. 2005;33(9):e86.
   PubMed Web of Science ®Google Scholar
• Siewert C, Haas H, Nawroth T, et al. Investigation of charge ratio variation in mRNA – DEAE-dextran polyplex delivery systems. Biomaterials. 2019;192:612–620.
   PubMed Web of Science ®Google Scholar
• Michel T, Link A, Abraham MK, et al. Generation of cationic nanoliposomes for the efficient delivery of in vitro transcribed messenger RNA. J Vis Exp. 2019Feb;1:144.
   Google Scholar
• Dirisala A, Uchida S, Tockary TA, et al. Precise tuning of disulphide crosslinking in mRNA polyplex micelles for optimizing extracellular and intracellular nuclease tolerability. J Drug Target. 2019;27(5–6):670–680.
   PubMed Web of Science ®Google Scholar
• Chen R, Zhang H, Yan J, et al. Scaffold-mediated delivery of non-viral mRNA vaccines. Gene Ther. 2018;25(8):556–567.
   PubMed Web of Science ®Google Scholar
• Tros de Ilarduya C, Arangoa MA, Duzgunes N. Transferrin-lipoplexes with protamine-condensed DNA for serum-resistant gene delivery. Methods Enzymol. 2003;373:342–356.
   PubMed Web of Science ®Google Scholar
• Kowalski PS, Rudra A, Miao L, et al. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol Ther. 2019;27(4):710–728.
   PubMed Web of Science ®Google Scholar
• Bell GD, Yang Y, Leung E. mRNA transfection by a Xentry-protamine cell-penetrating peptide is enhanced by TLR antagonist E6446. PLoS One. 2018;13(7):e0201464.
   PubMed Web of Science ®Google Scholar
• Coolen AL, Lacroix C, Mercier-Gouy P, et al. Poly(lactic acid) nanoparticles and cell-penetrating peptide potentiate mRNA-based vaccine expression in dendritic cells triggering their activation. Biomaterials. 2019;195:23–37.
   PubMed Web of Science ®Google Scholar
• Noble GT, Stefanick JF, Ashley JD, et al. Ligand-targeted liposome design: challenges and fundamental considerations. Trends Biotech. 2014;32(1):32–45.
   PubMed Web of Science ®Google Scholar
• Guevara M, Persano F, Persano S. Advances in lipid nanoparticles for mRNA-based cancer immunotherapy. Front Chem. 2020;8:589959.
   PubMed Web of Science ®Google Scholar
• Eygeris Y, Patel S, Jozic A, et al. Deconvoluting lipid nanoparticle structure for messenger RNA delivery. Nano Lett. 2020;20(6):4543–4549.
   PubMed Web of Science ®Google Scholar
• Vallazza B, Petri S, Poleganov M, et al. Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond. Wiley Interdiscipl Rev RNA. 2015;6:471–499.
   PubMed Web of Science ®Google Scholar
• Loomis K, Kirschman J, Bhosle S, et al. Strategies for modulatingInnate immune activation and protein production of in vitro transcribed mRNAs. J Mater Chem. 2016;4(9):1619–1632.
   Web of Science ®Google Scholar
• Yoshioka N, Gros E, Li HR, et al. Efficient generation of human iPSCs by a synthetic self-replicative RNA. Cell Stem Cell. 2013;13(2):246–254.
   PubMed Web of Science ®Google Scholar
• Jain R, Frederick JP, Huang EY, et al., MicroRNAs enable mRNA therapeutics to selectively program cancer cells to self-destruct. Nucleic Acid Ther. 28(5): 285–296. 2018.
   PubMed Web of Science ®Google Scholar
• Glisovic T, Bachorik JL, Yong J, et al. RNA-binding proteins and post-transcriptional gene regulation. FEBS Lett. 2008;582(14):1977–1986.
   PubMed Web of Science ®Google Scholar
• Dolicka D, Sobolewski C, Correia de Sousa M, et al. mRNA post-transcriptional regulation by AU-rich element-binding proteins in liver inflammation and cancer. Int J Mol Sci. 2020;21(18):6648.
   Web of Science ®Google Scholar